Search clinical trials for: MK-0677

Total 1709 results

Bennett, Robert, M.D.
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia

Fibromyalgia

United States
University of Virginia
Merck Sharp & Dohme LLC; National Institutes of Health (NIH)

Withdrawn

Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects

Chronic Kidney Disease | Kidney Disease

United States
University of Virginia
Merck Sharp & Dohme LLC; National Institutes of Health (NIH)

Completed

Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients

End Stage Renal Disease | Chronic Kidney Disease

United States
University of California, Los Angeles
Massachusetts General Hospital; Washington University School of Medicine; University... and other collaborators

Completed

Treatment Study for Cognitive Deficits in Schizophrenia (TURNS)

Schizophrenia

United States
University of Pittsburgh
Merck Sharp & Dohme LLC

Completed

Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study

Schizophrenia

United States
National Institute of Mental Health (NIMH)

Completed

Antidepressant Effects of NR2B in Major Depression

Major Depression

United States
Daiichi Sankyo, Inc.

Completed

12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients

Multiple Sclerosis

United States
Evolva SA

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects

Type 2 Diabetes

Germany
University of Virginia

Completed

Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults (MOT089)

Aging

United States
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Hepatitis C Virus Infection
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Greece, Israel, Italy, Mexico, New Zealand, Poland, Russian Federation, Sweden, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Hypertension | Isolated Systolic Hypertension
Merck Sharp & Dohme LLC

Completed

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Solid Tumors

United States, Canada, Switzerland
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Advanced Cancer
Merck Sharp & Dohme LLC

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Richter Transformation Lymphoma

Poland, United States, Canada, Chile, China, Estonia, Israel, Italy, Korea, Republic of, Spain, Sweden, Turkey, Czechia, Germany, Brazil, Portugal, Ireland, Singapore, United Kingdom, Japan, Peru
Merck Sharp & Dohme LLC

Completed

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

Ulcerative Colitis

United States, Georgia, Germany, Hungary, Moldova, Republic of, Poland, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)

Polysomnography
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of MK-8266 (MK-8266-001)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)

Hypertension

United States
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

Asthma

United States, Australia, New Zealand, South Africa
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Hepatitis C
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Completed

Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism (ACTICAS)

Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment

France
Merck Sharp & Dohme LLC

Completed

Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)

Primary Insomnia
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, Israel, South Africa
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study of MK-3614 (MK-3614-002)

Hypertension
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

Type 2 Diabetes
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)

Urinary Incontinence
Merck Sharp & Dohme LLC

Completed

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

Asthma
National Institute of Allergy and Infectious Diseases...

Completed

Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)

Migraine
Merck Sharp & Dohme LLC

Completed

Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)

Lymphoma | Solid Tumor

United States, Israel
Chinese University of Hong Kong

Recruiting

A Novel Integrative Non-invasive Embryo Selection Approach for in Vitro Fertilization Based on Artificial Intelligence Enhanced Morphokinetic Analysis and Raman Spectra in Spent Culture Media

IVF | Reproductive Issues | Subfertility

Hong Kong
Merck Sharp & Dohme LLC

Terminated

Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)

Hepatic Insufficiency | Antibacterial Agents

United States
Merck Sharp & Dohme LLC

Completed

Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)

Neoplasms | Cancer | Metastatic Solid Tumors | Locally Advanced Tumors
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)

Hepatitis C
Merck Sharp & Dohme LLC

Terminated

Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)

Neoplasms | Malignant
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Terminated

MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer

Brain and Central Nervous System Tumors

United States
ALK-Abelló A/S
Merck Sharp & Dohme LLC

Completed

A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)

Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Nonseasonal

3

Subscribe